BioDelivery Sciences International (NASDAQ:BDSI) has been under a strong bear grip, hence the stock is down -4.91% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 6.14% in the past 1 week. The stock has risen by 7.5% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.37% in the past 4 weeks.
The company shares have dropped -69.90% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $9.91 and the one year low was seen on May 23, 2016. The 50-Day Moving Average price is $2.36 and the 200 Day Moving Average price is recorded at $3.27.
The stock has recorded a 20-day Moving Average of 6.22% and the 50-Day Moving Average is 6.56%.
BioDelivery Sciences International (NASDAQ:BDSI): stock turned positive on Friday. Though the stock opened at $2.55, the bulls momentum made the stock top out at $2.62 level for the day. The stock recorded a low of $2.461 and closed the trading day at $2.58, in the green by 2.79%. The total traded volume for the day was 632,617. The stock had closed at $2.51 in the previous days trading.
In an insider trading activity, Bramlage Charles, director of Biodelivery Sciences International Inc, had purchased 8,850 shares on March 21, 2016. The total value of the transaction was $24,957. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.